No Detail Found!

Drug repurposing: identification of potential drug targets against nonstructural protein 1 (NSP-1) of sars-cov-2 through molecular docking and molecular dynamic simulation using FDA approved drugs

Author(s)
Rana Muhammad Mateen Center for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan; Department of Life sciences, School of Science, University of Management and Technology, Lahore 54770, Pakistan.
Muhammad Arif Nadeem Saqib Department of Medical Lab Technology, National Skill University, Islamabad, Pakistan
Mureed Hussain Department of Life sciences, School of Science, University of Management and Technology,Lahore 54770,Pakistan
Muhammad Irfan Fareed Department of Life sciences, School of Science, University of Management and Technology,Lahore 54770,Pakistan
Iqra Naeem Department of Life sciences, School of Science, University of Management and Technology,Lahore 54770,Pakistan
Muhammad Sohail Afzaal Department of Life sciences, School of Science, University of Management and Technology,Lahore 54770,Pakistan
Rukhsana Parveen Center for Applied Molecular Biology, University of the Punjab,Lahore,Pakistan
Abstract
Since its pandemic in 2019, SARS-CoV-2 has badly affected the countries around the globe. There is no FDA approved drug for the treatment of the disease. In this study, we evaluated potential targets against non-structural protein-1 (Nsp-1), which is crucial in disturbing host-translational machinery. As the complete crystal structure of the Nsp-1 was not available, we used I-TASSER for making the complete structure of the protein. The structure was verified using ERRAT and PROVEAN. As the previous studies had reported different binding sites for this protein, we used blind docking of Nsp-1 with 2225 FDA approved drugs using AutoDock Vina. Based upon the residue interactions obtained from the blind docking, we selected C-terminal of Nsp-1 for specific docking against FDA approved drugs. Based upon the docking results, Glycyrrhizin was found to be suitable drug showing strong interactions. We further verified the glycyrrhizinNsp-1 complex by analyzing the trajectory for 60 ns, by comparing with individual protein. RMSD analysis during the trajectory and RMSF analysis also suggested the stability of the protein-ligand complex and resulted in 49 hydrogen bonds during the simulation process. The study suggests that Glycyrrhizin can act as potential inhibitors against Nsp-1 of SARS-COV-2.
Publication Details
Page(s) 161-178
DOI DOI not available
Published Journal: The Journal of Microbiology and Molecular Genetics, Volume: 3, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
COVID-19, SARS-CoV-2, drug designing, in silico, Drug Repurposing, Nsp-1
0

Citations

0

Downloads

44

Views